Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of ...

Pictet Asset Management boosted its Johnson & Johnson holdings by 12.3%, adding over 155,000 shares in Q4. This raised its ...

Nearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million in a lawsuit alleging that ...

MedTech has launched the Dualto Energy System, an electrosurgical generator that unites various energy modalities into an ...

Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...

A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64B after a jury found it liable in a ...

Johnson & Johnson shares ended Monday doing the financial equivalent of shrugging, trading flat despite some analyst action.

Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D ...

Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

Guggenheim analyst Yatin Suneja notes Johnson & Johnson (JNJ) released two abstract titles for the upcoming European Congress of ...

J&J's Rybrevant and Lazcluze combination reduced the risk of death by 25% compared to AstraZeneca’s Tagrisso in NSCLC.